Edmund Miller, DO
Family Medicine · Tupelo, MSNPI 1689089203
Payments from drug & device makers
Across 200 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$617
- Lilly USA, LLC$547
- Novo Nordisk$475
- AbbVie$409
- Bayer$252
- QOL Medical, LLC$159
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,568100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $617 |
| Lilly USA, LLC | 29 | $547 |
| Novo Nordisk | 25 | $475 |
| AbbVie | 22 | $409 |
| Bayer | 15 | $252 |
| QOL Medical, LLC | 6 | $159 |
| Boehringer Ingelheim | 10 | $148 |
| Teva Pharmaceuticals USA, Inc. | 9 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $122 |
| Pfizer | 8 | $113 |
| Exact Sciences | 6 | $88 |
| Merck | 5 | $76 |
| Sanofi-aventis U.S. LLC | 5 | $72 |
| GSK | 4 | $65 |
| Lundbeck LLC | 2 | $47 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Amgen | 3 | $36 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Vertex | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
How this compares
$3,568 in reported general payments places this provider in the 80th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 209 | $261,508 |
| EliquisApixaban | 703 | $240,482 |
| MounjaroTirzepatide | 134 | $155,781 |
| FarxigaDapagliflozin Propanediol | 166 | $129,387 |
| JardianceEmpagliflozin | 162 | $124,829 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 121 | $74,778 |
| XareltoRivaroxaban | 63 | $44,858 |
| EntrestoSacubitril/Valsartan | 47 | $43,017 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 36 | $42,892 |
| SynjardyEmpagliflozin/Metformin Hcl | 29 | $42,598 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $37,676 |
| LinzessLinaclotide | 53 | $32,918 |
| JanuviaSitagliptin Phosphate | 92 | $31,407 |
| Tresiba Flextouch U-100Insulin Degludec | 52 | $27,388 |
| RexultiBrexpiprazole | 42 | $27,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $475 | $261,508209 claims |
| PfizerEliquis | $113 | $240,482703 claims |
| Boehringer IngelheimJardiance, Synjardy, Combivent Respimat | $148 | $176,614207 claims |
| Lilly USA, LLCMounjaro | $547 | $155,781134 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $617 | $150,029186 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $72 | $50,113111 claims |
| Johnson & JohnsonXarelto | $12 | $44,85863 claims |
| MerckJanuvia, Janumet | $76 | $43,696107 claims |
| AbbVieLinzess, Restasis | $409 | $42,49367 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $30 | $27,36342 claims |
| GSKTrelegy Ellipta | $65 | $19,01529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Tupelo
- Jeanne BensonTupelo$13K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.